With your support, we have been able to fund outstanding research, leading toward cures and improved quality of life for children with cancer. Browse through more than 1,000 funded projects below.
Use the search tool to refine your results. You can also click on a heading to sort by project title, institution name, or year the grant was awarded. Click on the project title to read more information.
ALSF Funded Research Projects
|Project Title||Institution / Principal Investigator(s)||Grant Type||Year||State|
|Nitrosative Stress And Symptom Severity During Childhood Leukemia Treatment||Duke University Medical Center / Marilyn Hockenberry, RN, PhD||Nurse Researcher Grants||2013||North Carolina|
|Dissecting the Hierarchy of Tumor Cell Differentiation Using Dual Recombinase Technology in a Novel Mouse Model of Rhabdomyosarcoma||Duke University Medical Center / David Van Mater, MD, PhD||Young Investigator Grants||2013||North Carolina|
|Therapeutic Potential of the MST1/Hippo Tumor Suppressor Pathway in Alveolar Rhabdomyosarcoma||Duke University / Corinne Mary Linardic, MD, PhD||Innovation Grants||2013||North Carolina|
|Function of the PR Domain of the MDSI-EVI1 in MLL Fusion Protein Leukemogenesis||University of Rochester / Archibald Perkins, MD, PhD||Springboard Grants||2013||New York|
|Epigenomics of High Risk Pediatric T Cell Leukemia||New York University School of Medicine / Iannis Aifantis, PhD||Reach Grants||2013||New York|
|Rational Combination Therapy of AML||Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD, PhD||'A' Award Grants||2013||New York|
|Columbia University Developmental Therapeutics Program: Striving for Excellence||Columbia University / Julia Glade Bender, MD||Phase I/II Infrastructure Grants||2013||New York|
|Identification of TFAP4 (Transcription Factor AP-4/Activating Enhancer Binding Protein) as a Potential Master Regulator/Synthetic Lethal Gene of MYCN Amplified Neuroblastoma||Columbia University Medical Center / Darrell Yamashiro, MD, PhD||Innovation Grants||2013||New York|
|Therapeutic Targeting of LARG-RhoA Signaling Axis in Childhood Leukemia||Cincinnati Children's Hospital Medical Center / Yi Zheng, PhD||Innovation Grants||2013||Ohio|
|Nationwide Children's Hospital Phase I/II Infrastructure||Research Institute at Nationwide Children's Hospital / Sarah O'Brien, MD and Timothy Cripe, MD, PhD||Phase I/II Infrastructure Grants||2013||Ohio|